ClinicalTrials.Veeva

Menu

Biomarkers in DNA Samples From Patients With High-Risk Acute Lymphoblastic Leukemia

C

Children's Oncology Group

Status

Completed

Conditions

Leukemia

Treatments

Genetic: polymorphism analysis
Genetic: microarray analysis
Genetic: genetic linkage analysis
Genetic: nucleic acid sequencing
Genetic: DNA analysis
Other: laboratory biomarker analysis
Genetic: polymerase chain reaction

Study type

Observational

Funder types

NETWORK
NIH

Identifiers

NCT01119586
CDR0000672526 (Other Identifier)
AALL10B2
NCI-2011-02232 (Registry Identifier)
COG-AALL10B2 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is studying biomarkers in DNA samples from patients with newly diagnosed high-risk acute lymphoblastic leukemia.

Full description

OBJECTIVES:

  • To perform pooled DNA sequencing in 56 genes from the genomic DNA of unaffected children and matched non-tumor and blast DNA from patients with high-risk (HR) acute lymphoblastic leukemia (ALL) enrolled on COG HR ALL protocols.
  • To identify loci enriched for genetic variation between DNA of unaffected children and DNA of these patients.
  • To individually validate novel, putatively functional single nucleotide polymorphisms (SNPs) identified via pooled sequencing with another genotyping platform.
  • To correlate HR ALL with clinical phenotypes, co-morbidities, toxicities, outcomes to the genes or pathways found to harbor a significant increase in genetic variation.

OUTLINE: DNA specimens from unaffected children (pool 1) and from patients with non-tumor (pool 2) and leukemia blasts (pool 3) are analyzed for genetic pathophysiology of pre-B acute lymphoblastic leukemia by microarray and PCR assays. Sequencing is performed on each of the 3 PCR pools of DNA.

Enrollment

350 estimated patients

Sex

All

Ages

1 to 30 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

  • Newly diagnosed with high-risk B-precursor acute lymphoblastic leukemia

    • Matched patients non-tumor and blast DNA samples
    • Enrolled on COG-P9906 or COG-AALL0232 protocols
  • Cohort of random pediatric DNA samples extracted from newborn infants' blood spots from the State of Missouri

PATIENT CHARACTERISTICS:

  • Newborn infants from the state of Missouri

PRIOR CONCURRENT THERAPY:

  • Not specified

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems